Giuseppe Limongelli
A5049562211- Cardiomyopathy and Myosin Studies
- Cardiovascular Function and Risk Factors
- Cardiovascular Effects of Exercise
- Congenital Heart Disease Studies
- Heart Failure Treatment and Management
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac pacing and defibrillation studies
- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Viral Infections and Immunology Research
- Cardiac Arrhythmias and Treatments
- Lysosomal Storage Disorders Research
- Cardiovascular and exercise physiology
- Protein Tyrosine Phosphatases
- Cardiac Imaging and Diagnostics
- Congenital heart defects research
- Galectins and Cancer Biology
- Parathyroid Disorders and Treatments
- Pulmonary Hypertension Research and Treatments
- Cardiac electrophysiology and arrhythmias
- Trypanosoma species research and implications
- Mitochondrial Function and Pathology
- Aortic Disease and Treatment Approaches
- Peptidase Inhibition and Analysis
- Cardiovascular Issues in Pregnancy
University of Campania "Luigi Vanvitelli"
2016-2025
University College London
2015-2025
Ospedale Monaldi
2016-2025
Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli
2018-2024
University of Naples Federico II
2012-2024
European Society of Cardiology
2024
Regione Campania
2020-2024
ERN GUARD-Heart
2018-2024
Ospedale Papa Giovanni XXIII
2016-2024
Centro Cardiologico Monzino
2013-2024
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their dating.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relationship to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
AimsHypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. Current risk algorithms provide only crude estimate and fail to account for the different effect size individual factors. The aim this study was develop validate new SCD prediction model that provides individualized estimates.
2D : two-dimensional 99mTc-DPD : 99mTechnetium-3,3-diphosphono- 1,2-propanodi-carboxylic acid ACE : angiotensin-converting enzyme AF : atrial fibrillation AL : amyloid light chain AR : aortic regurgitation ARB : angiotensin receptor blocker ATTR : amyloidosis-transthyretin type AV : atrioventricular BiVAD : biventricular assist device BNP : brain natriuretic peptide BPM : Beats per minute CCS : Canadian Cardiovascular Society CFC : cardiofacialcutaneous CHA2DS2-VASc : Congestive Heart...
Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesterase-inhibitors, increased Newer drugs, levosimendan omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2+. Although meta-analyses smaller trials suggested a better outcome than dobutamine, larger comparative failed...
Sudden cardiac death (SCD) is the most common mode of in childhood hypertrophic cardiomyopathy (HCM), but there no validated algorithm to identify those at highest risk.
Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by pathogenic variants in the α‐galactosidase A ( GLA ) gene that leads to reduced or undetectable enzyme activity and progressive accumulation of globotriaosylceramide its deacylated form globotriaosylsphingosine cells throughout body. FD can be multisystemic with neurological, renal, cutaneous cardiac involvement limited heart. Cardiac characterized hypertrophy, fibrosis, arrhythmias, heart failure sudden death. The...
Atrial fibrillation (AF) and thrombo-embolism (TE) are associated with reduced survival in hypertrophic cardiomyopathy (HCM), but the absolute risk of TE patients without AF is unclear. The primary aim this study was to derive validate a model for estimating HCM. Exploratory analyses were performed determine predictors TE, performance CHA2 DS2 -VASc score, outcome vitamin K antagonists (VKAs).A retrospective, longitudinal cohort seven institutions used develop multivariable Cox regression...
The pathogenesis of transposition the great arteries (TGA) is still largely unknown. In general, TGA not associated with more common genetic disorders nor extracardiac anomalies, whereas it can be found in individuals lateralisation defects, heterotaxy and asplenia syndrome (right isomerism).To analyse genes previously order to assess mutations familial unassociated other features laterality defects.Probands seven families isolated a family history concordant or discordant congenital heart...
Cardiovascular abnormalities are important features of Costello syndrome and other Ras/MAPK pathway syndromes ("RASopathies"). We conducted clinical, pathological molecular analyses 146 patients with an HRAS mutation including 61 enrolled in ongoing longitudinal study 85 from the literature. In our study, most common (84%) was p.G12S. A congenital heart defect (CHD) present 27 (44%), usually non-progressive valvar pulmonary stenosis. Hypertrophic cardiomyopathy (HCM), typically subaortic...
The Cardiomyopathy Registry of the EURObservational Research Programme is a prospective, observational, and multinational registry consecutive patients with four cardiomyopathy subtypes: hypertrophic (HCM), dilated (DCM), arrhythmogenic right ventricular (ARVC), restrictive (RCM). We report baseline characteristics management adults enrolled in registry. A total 3208 were by 69 centres 18 countries [HCM (n = 1739); DCM 1260); ARVC 143); RCM 66)]. Differences between subtypes (P < 0.001)...